Inhibrx Biosciences, Inc. (NASDAQ:INBX) — Market Cap & Net Worth
Market Cap & Net Worth: Inhibrx Biosciences, Inc. (INBX)
Inhibrx Biosciences, Inc. (NASDAQ:INBX) has a market capitalization of $1.38 Billion ($1.38 Billion) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7735 globally and #2244 in its home market, demonstrating a 5.72% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Inhibrx Biosciences, Inc.'s stock price $94.20 by its total outstanding shares 14607286 (14.61 Million). Review debt load of Inhibrx Biosciences, Inc. to assess the company's total debt and financial obligations.
Inhibrx Biosciences, Inc. Market Cap History: 2020 to 2026
Inhibrx Biosciences, Inc.'s market capitalization history from 2020 to 2026. Data shows growth from $481.60 Million to $1.38 Billion (29.76% CAGR).
Index Memberships
Inhibrx Biosciences, Inc. is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.06% | #214 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #828 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.08% | #133 of 263 |
Weight: Inhibrx Biosciences, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Inhibrx Biosciences, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Inhibrx Biosciences, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
887.67x
Inhibrx Biosciences, Inc.'s market cap is 887.67 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $481.60 Million | $12.81 Million | -$75.64 Million | 37.60x | N/A |
| 2021 | $637.90 Million | $7.12 Million | -$81.77 Million | 89.53x | N/A |
| 2022 | $359.92 Million | $2.19 Million | -$145.23 Million | 164.20x | N/A |
| 2023 | $555.08 Million | $1.80 Million | -$241.36 Million | 308.38x | N/A |
| 2024 | $224.95 Million | $200.00K | $1.69 Billion | 1124.76x | 0.13x |
| 2025 | $1.15 Billion | $1.30 Million | -$140.06 Million | 887.67x | N/A |
Competitor Companies of INBX by Market Capitalization
Companies near Inhibrx Biosciences, Inc. in the global market cap rankings as of June 18, 2026.
Key companies related to Inhibrx Biosciences, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Inhibrx Biosciences, Inc. Historical Marketcap From 2020 to 2026
Between 2020 and today, Inhibrx Biosciences, Inc.'s market cap moved from $481.60 Million to $ 1.38 Billion, with a yearly change of 29.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.38 Billion | +19.24% |
| 2025 | $1.15 Billion | +412.99% |
| 2024 | $224.95 Million | -59.47% |
| 2023 | $555.08 Million | +54.22% |
| 2022 | $359.92 Million | -43.58% |
| 2021 | $637.90 Million | +32.45% |
| 2020 | $481.60 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Inhibrx Biosciences, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.38 Billion USD |
| MoneyControl | $1.38 Billion USD |
| MarketWatch | $1.38 Billion USD |
| marketcap.company | $1.38 Billion USD |
| Reuters | $1.38 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-bas… Read more